peripheral arterial disease pad drug pipeline analysis and market forecasts to 2016 n.
Skip this Video
Loading SlideShow in 5 Seconds..
peripheral arterial disease (pad) - drug pipeline analysis PowerPoint Presentation
Download Presentation
peripheral arterial disease (pad) - drug pipeline analysis

Loading in 2 Seconds...

play fullscreen
1 / 3

peripheral arterial disease (pad) - drug pipeline analysis - PowerPoint PPT Presentation

  • Uploaded on

The PAD Therapeutics Market is forecast to Show Modest Growth until 2016

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'peripheral arterial disease (pad) - drug pipeline analysis' - rgunnam

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

The PAD Therapeutics Market is forecast to Show Modest Growth until 2016

The global peripheral arterial disease (PAD) therapeutics market was worth approximately $897m in 2009. In 2001, the market was valued at $568m and it grew at an approximate CAGR of 5.9% between 2001 and 2009. The global PAD therapeutics market is expected to reach $1.3 billion by 2016 after growing at a CAGR of 6.1% between 2001 and 2016. The primary factor contributing to the increase in growth over the forecast period is the increase in disease incidence. Presently the therapeutic regimen for PAD consists of antiplatelet agents such as Clopidogrel (Plavix) and Ticlopidine (Ticlid). Blood thinners such as Pentoxifyline (Trental) and Cilostazol (Pletal) are also prescribed. As with most cardiovascular complications, Asprin is used as a complementary drug in combination with the above mentioned drugs. The PAD therapeutics market is dominated by generics. Tablet prices range between $0.75 and $2 depending on the brand. The average annual cost of therapy for PAD therapeutics ranges between $300 and $675.

The PAD Therapeutics Market Pipeline is Relatively Weak

The market has limited scope for growth due to the presence of generic products and the lack of innovation with respect to better efficacy and safety drug profiles. The developmental pipeline is weak with only 34 molecules in various phases of clinical development. There are 16 first-in-class molecules over all the phases of development. The mechanism of action of 11 drugs was not disclosed by the parent company. Phase III contains three first-in-class molecules. These include platelet aggregation inhibitors and granulocyte and macrophage proliferation, and differentiation stimulators and combinational therapies employing molecules with these two mechanisms of action. Phase II contains eight first-in-class molecules. Molecules such as Saproprotein and HGF DNA Plasmid employ novel mechanisms of action.

For further details, please visit or add the below link to your browser:


The PAD Therapeutics Market Has High Unmet Needs to be Addressed

The PAD therapeutics market has unmet needs in terms of both efficacy and safety. These unmet needs imply that the market is moderately served by the current product options and has wide scope available for new entrants that can capture value from the underserved segments. The efficacy of the present therapeutics is moderate to strong with a couple of therapeutic classes with strong efficacy profiles. The therapeutic interventions for PAD are limited to oral formulations in tablet form. Since the market is dominated by generics, the price of drugs is relatively low.

Safety, is a major concern for this market. The occurrence of bleeding complications such as thrombocytopenia, ecchymosis, epistaxis, hematuria and conjunctival hemorrhage are prevalent among the patient population and there is a need for safer drugs. Apart from these complications, nausea, vomiting and diarrhea are also significant side effects of the present PAD therapeutics. The need for safer drugs, especially with respect to the target population of patients between the ages of 50 and 77 years, is the primary unmet need for the PAD therapeutics market.

GlobalData, the industry analysis specialist’s new report, “Peripheral Arterial Disease - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global peripheral arterial disease market. The report identifies the key trends shaping and driving the global peripheral arterial disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global peripheral arterial disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

For further details, please visit or add the below link to your browser:

Or visit our report store:

Contact Information

Rajesh Gunnam